• Stephen A Goutman, Orla Hardiman, Ammar Al-Chalabi, Adriano Chió, Masha G Savelieff, Matthew C Kiernan, and Eva L Feldman.
• Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
• Lancet Neurol. 2022 May 1; 21 (5): 480493480-493.

AbstractThe diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in clinical presentation and overlap with other neurological disorders. Diagnosis early in the disease course can improve outcomes as timely interventions can slow disease progression. An evolving awareness of disease genotypes and phenotypes and new diagnostic criteria, such as the recent Gold Coast criteria, could expedite diagnosis. Improved prognosis, such as that achieved with the survival model from the European Network for the Cure of ALS, could inform the patient and their family about disease course and improve end-of-life planning. Novel staging and scoring systems can help monitor disease progression and might potentially serve as clinical trial outcomes. Lastly, new tools, such as fluid biomarkers, imaging modalities, and neuromuscular electrophysiological measurements, might increase diagnostic and prognostic accuracy.Copyright © 2022 Elsevier Ltd. All rights reserved.

22 keywords...

hide…